Last reviewed · How we verify
Isooncotic Albumin 5%
Isooncotic Albumin 5% is a Colloid volume expander Small molecule drug developed by Insel Gruppe AG, University Hospital Bern. It is currently FDA-approved for Acute hypovolemia and plasma loss (burns, trauma, major surgery), Hypoproteinemia and associated edema in chronic conditions. Also known as: Albumin 5%.
Isooncotic albumin 5% is a colloid solution that maintains oncotic pressure to restore and maintain intravascular volume in patients with hypovolemia or plasma loss.
Isooncotic albumin 5% is a colloid solution that maintains oncotic pressure to restore and maintain intravascular volume in patients with hypovolemia or plasma loss. Used for Hypovolemia and plasma loss in severe burns, Volume expansion in major surgery and trauma, Hypoalbuminemia in critical illness.
At a glance
| Generic name | Isooncotic Albumin 5% |
|---|---|
| Also known as | Albumin 5% |
| Sponsor | Insel Gruppe AG, University Hospital Bern |
| Drug class | Colloid volume expander |
| Modality | Small molecule |
| Therapeutic area | Critical Care / Hematology |
| Phase | FDA-approved |
Mechanism of action
Albumin is a naturally occurring plasma protein that exerts oncotic (colloid osmotic) pressure, drawing and retaining fluid in the intravascular space. The 5% isooncotic formulation is isotonic with plasma and is used as a volume expander in acute blood loss, burns, surgery, and other conditions causing significant fluid loss. It helps restore circulating blood volume and maintain hemodynamic stability without the risks associated with crystalloid-only resuscitation.
Approved indications
- Acute hypovolemia and plasma loss (burns, trauma, major surgery)
- Hypoproteinemia and associated edema in chronic conditions
Common side effects
- Hypervolemia / fluid overload
- Allergic reactions
- Fever
- Hypotension
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Isooncotic Albumin 5% CI brief — competitive landscape report
- Isooncotic Albumin 5% updates RSS · CI watch RSS
- Insel Gruppe AG, University Hospital Bern portfolio CI
Frequently asked questions about Isooncotic Albumin 5%
What is Isooncotic Albumin 5%?
How does Isooncotic Albumin 5% work?
What is Isooncotic Albumin 5% used for?
Who makes Isooncotic Albumin 5%?
Is Isooncotic Albumin 5% also known as anything else?
What drug class is Isooncotic Albumin 5% in?
What development phase is Isooncotic Albumin 5% in?
What are the side effects of Isooncotic Albumin 5%?
Related
- Drug class: All Colloid volume expander drugs
- Manufacturer: Insel Gruppe AG, University Hospital Bern — full pipeline
- Therapeutic area: All drugs in Critical Care / Hematology
- Indication: Drugs for Acute hypovolemia and plasma loss (burns, trauma, major surgery)
- Indication: Drugs for Hypoproteinemia and associated edema in chronic conditions
- Also known as: Albumin 5%